Spero Therapeuti Stock Price, News & Analysis

Spero Therapeutics (NASDAQ: SPRO) reported Q1 2025 financial results and provided key updates. The company posted a net loss of $13.9 million ($0.25 per share) compared to $12.7 million loss in Q1 2024. Total revenue decreased to $5.9 million from $9.3 million year-over-year. The company's lead candidate, tebipenem HBr, an oral carbapenem antibiotic for complicated urinary tract infections, is progressing with a pre-specified interim analysis of Phase 3 PIVOT-PO trial expected in Q2 2025. The company appointed Esther Rajavelu as President and CEO effective May 2, 2025. Spero ended Q1 with $48.9 million in cash, which, combined with $23.75M in upcoming GSK milestone payments, is expected to fund operations into Q2 2026. The SPR720 program for NTM-PD was suspended in Q4 2024 after failing to meet primary endpoints in Phase 2a study.

Spero Therapeutics (NASDAQ: SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant bacterial infections treatments, will release its first quarter 2025 financial results after market close on Tuesday, May 13, 2025. The company will also provide a business update but has stated it will not host a conference call for this earnings announcement.

Spero Therapeutics has appointed Esther Rajavelu as permanent President and Chief Executive Officer, effective May 2, 2025. Rajavelu, who has been serving as Interim CEO since January 2025, will continue her role as Chief Financial Officer and Treasurer while also being nominated to the Board of Directors.

Key highlights:

• Rajavelu has been with Spero since November 2023, serving as CFO, Treasurer, and Chief Business Officer
• She succeeds Sath Shukla, who will step down from both CEO position and Board membership on May 2, 2025
• The company is preparing for an update on their PIVOT-PO Phase 3 trial for tebipenem HBr this quarter
• Board Chairman Frank Thomas praised Rajavelu's leadership and experience in biopharma financing

This leadership transition comes at a crucial time as Spero Therapeutics, a clinical-stage biopharma company, continues its focus on rare diseases and multi-drug resistant bacterial infections, with the tebipenem HBr program being their highest priority.

Spero Therapeutics (SPRO) announced its Q4 and full-year 2024 financial results, reporting a net loss of $(20.9) million for Q4 and $(68.6) million for the full year. Total revenue decreased to $15.0 million in Q4 2024 from $73.5 million in Q4 2023.

Key pipeline updates include:

• Pre-specified interim analysis of Phase 3 PIVOT-PO trial for tebipenem HBr in complicated urinary tract infection expected in Q2 2025
• SPR720 program for NTM-PD under review following missed primary endpoint in Phase 2 study
• SPR206 program discontinued after pipeline reprioritization in Q1 2025

The company's cash position stands at $52.9 million, with runway extending into Q2 2026, supported by GSK milestone payments. Leadership changes include Esther Rajavelu's appointment as Interim CEO following a SEC Wells Notice related to certain public disclosures from March-May 2022.

Spero Therapeutics (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on rare diseases and multi-drug resistant bacterial infections, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 27, 2025.

The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss results and provide business updates. Investors can access the call via domestic (1-844-825-9789) or international (1-412-317-5180) dial-in numbers using conference ID 10196669.

Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant bacterial infections treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference.

The conference will take place in Boston from March 3rd to 5th, 2025, where Esther Rajavelu, Spero's Interim President and CEO, will present and be available for one-on-one meetings. Interested parties can access the presentation webcast through Spero Therapeutics' website under the 'Events and Presentations' section, with a replay available after the event.

Spero Therapeutics (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections, has announced its participation in the TD Cowen 45th Annual Health Care Conference.

The conference will be held in Boston from March 3-5, 2025, where Esther Rajavelu, Spero's Interim President and CEO, will present and be available for one-on-one meetings with interested parties.

Those interested in scheduling meetings can contact their institutional representative or email for details. A webcast of the presentation will be accessible through Spero Therapeutics' website on the "Events and Presentations" page under the "Connect" tab, with a replay available after the event concludes.

Spero Therapeutics (SPRO) announced interim leadership changes in response to an SEC Wells Notice regarding certain public disclosures made in 2022. Esther Rajavelu has been appointed Interim President and CEO, replacing Sath Shukla who has taken voluntary paid administrative leave. Frank Thomas has been appointed Chairman of the Board, replacing Dr. Ankit Mahadevia.

The company reported that its Phase 3 PIVOT-PO trial of Tebipenem HBr has reached over 60% enrollment as of December 31, 2024, and remains on track for completion in 2H 2025. The trial aims to enroll approximately 2,648 participants for testing this oral carbapenem antibiotic for complicated urinary tract infections.

Spero reported $52.9 million in cash and cash equivalents (unaudited) as of December 31, 2024, maintaining its cash runway guidance into mid-2026. The company's SPR720 Phase 2a trial did not meet its primary endpoint, with safety concerns noted at the 1,000mg dose level.

Spero Therapeutics (SPRO) reported Q3 2024 financial results with a net loss of $17.1 million ($0.32 per share), compared to $3.2 million loss in Q3 2023. Revenue decreased to $13.5 million from $25.5 million year-over-year. The company's Phase 3 PIVOT-PO trial for tebipenem HBr remains on track for enrollment completion in 2H 2025. Following SPR720 development suspension and a 39% workforce reduction, cash position stands at $76.3 million, extending runway into mid-2026. R&D expenses increased to $26.9 million from $16.4 million, while G&A expenses decreased to $5.2 million from $5.7 million year-over-year.